COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne)

被引:18
作者
Hsu, Lea [1 ,2 ]
Gruene, Barbara [1 ]
Buess, Michael [1 ]
Joisten, Christine [1 ,3 ]
Klobucnik, Jan [1 ]
Niessen, Johannes [1 ]
Patten, David [1 ]
Wolff, Anna [1 ]
Wiesmueller, Gerhard A. [1 ,2 ]
Kossow, Annelene [1 ,4 ]
Hurrass, Julia [1 ]
机构
[1] Publ Hlth Dept Cologne, Infekt & Umwelthyg, D-50667 Cologne, Germany
[2] Rhein Westfal TH Aachen, Univ Hosp, Inst Occupat Med & Social Med, Med Fac, D-52056 Aachen, Germany
[3] German Sport Univ Cologne, Inst Movement & Neurosci, Dept Phys Act Publ Hlth, Sportpk Mungersdorf 6, D-50933 Cologne, Germany
[4] Univ Hosp Muenster, Inst Hyg, D-48149 Munster, Germany
关键词
COVID-19; vaccination; breakthrough infections; SARS-CoV-2; pandemic; transmission; VACCINE;
D O I
10.3390/vaccines9111267
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and Methods: Vaccination is currently considered the most successful strategy for combating the SARS-CoV-2 virus. According to short-term clinical trials, protection against infection is estimated to reach up to 95% after complete vaccination (& GE;14 days after receipt of all recommended COVID-19 vaccine doses). Nevertheless, infections despite vaccination, so-called breakthrough infections, are documented. Even though they are more likely to have a milder or even asymptomatic course, the assessment of further transmission is highly relevant for successful containment. Therefore, we calculated the real-world transmission risk from fully vaccinated patients (vaccination group, VG) to their close contacts (CP) compared with the risk from unvaccinated reference persons matched according to age, sex, and virus type (control group = CG) utilizing data from Cologne's health department. Results: A total of 357 breakthrough infections occurred among Cologne residents between 27 December 2020 (the date of the first vaccination in Cologne) and 6 August 2021. Of the 979 CPs in VG, 99 (10.1%) became infected. In CG, 303 of 802 CPs (37.8%) became infected. Factors promoting transmission included non-vaccinated status (beta = 0.237; p < 0.001), male sex (beta = 0.079; p = 0.049), the presence of symptoms (beta = -0.125; p = 0.005), and lower cycle threshold value (beta = -0.125; p = 0.032). This model explained 14.0% of the variance (corr. R-2). Conclusion: The number of transmissions from unvaccinated controls was three times higher than from fully vaccinated patients. These real-world data underscore the importance of vaccination in enabling the relaxation of stringent and restrictive general pandemic control measures.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Toward Accurate Spatiotemporal COVID-19 Risk Scores Using High-Resolution Real-World Mobility Data
    Rambhatla, Sirisha
    Zeighami, Sepanta
    Shahabi, Kameron
    Shahabi, Cyrus
    Liu, Yan
    ACM TRANSACTIONS ON SPATIAL ALGORITHMS AND SYSTEMS, 2022, 8 (02)
  • [22] Risk Perception in a Real-World Situation (COVID-19): How It Changes From 18 to 87 Years Old
    Rosi, Alessia
    van Vugt, Floris Tijmen
    Lecce, Serena
    Ceccato, Irene
    Vallarino, Martine
    Rapisarda, Filippo
    Vecchi, Tomaso
    Cavallini, Elena
    FRONTIERS IN PSYCHOLOGY, 2021, 12
  • [23] Integrating real-world data from Brazil and Pakistan into the OMOP common data model and standardized health analytics framework to characterize COVID-19 in the Global South
    Pinto, Elzo Pereira, Jr.
    Normando, Priscilla
    Flores-Ortiz, Renzo
    Afzal, Muhammad Usman
    Jamil, Muhammad Asaad
    Bertolin, Sergio Fernandez
    Oliveira, Vinicius de Araujo
    Martufi, Valentina
    de Sousa, Fernanda
    Bashir, Amir
    Burn, Edward
    Ichihara, Maria Yury
    Barreto, Mauricio L.
    Salles, Talita Duarte
    Prieto-Alhambra, Daniel
    Hafeez, Haroon
    Khalid, Sara
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2023, 30 (04) : 643 - 655
  • [24] Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization
    Moghnieh, Rima
    Haddad, Wajdi
    Jbeily, Nayla
    El-Hassan, Salam
    Eid, Shadi
    Baba, Hicham
    Sily, Marilyne
    Saber, Yara
    Abdallah, Dania
    Bizri, Abdul Rahman
    Sayegh, Mohamed H.
    PLOS ONE, 2024, 19 (09):
  • [25] Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey
    Kilavuz, S.
    Kor, D.
    Bulut, F. D.
    Serbes, M.
    Karagoz, D.
    Altintas, D. U.
    Bisgin, A.
    Seydaoglu, G.
    Mungan, H. N. O.
    ARCHIVES DE PEDIATRIE, 2022, 29 (06): : 415 - 423
  • [26] A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data
    Grima, Simon
    Rupeika-Apoga, Ramona
    Kizilkaya, Murat
    Romanova, Inna
    Gonzi, Rebecca Dalli
    Jakovljevic, Mihajlo
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2021, 14 : 4775 - 4787
  • [27] Statins use amidst the pandemic: prescribing, dispensing, adherence, persistence, and correlation with COVID-19 statistics in nationwide real-world data from Poland
    Kardas, Przemyslaw
    Kwiatek, Angelika
    Wlodarczyk, Piotr
    Urbanski, Filip
    Ciabiada-Bryla, Beata
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] Children in the COVID-19 pandemic and the public health service (oGD) Data and reflections from Frankfurt am Main, Germany
    Heudorf, Ursel
    Gottschalk, Rene
    Walczok, Antoni
    Tinnemann, Peter
    Steul, Katrin
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2021, 64 (12) : 1559 - 1569
  • [29] COVID-19 Insights Partnership: Leveraging big data from the Department of Veterans Affairs and supercomputers at the Department of Energy under the public health authority
    Ramoni, Rachel
    Klote, Molly
    Muralidhar, Sumitra
    Brandt, Cynthia
    Bernstein, Maya A.
    McMahon, Benjamin H.
    Jacobson, Daniel A.
    Justice, Amy C.
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2021, 28 (07) : 1578 - 1581
  • [30] Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
    Gmizic, Ivana I.
    Barac, Aleksandra
    Todorovic, Nevena
    Sabanovic, Milos
    Kekic, Natalija
    Boskovic, Nikola
    Vujovic, Ankica
    Nikolic, Natasa
    Knezevic, Natasa
    Milosevic, Ivana
    Stevanovic, Goran
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2024, 18 (05): : 694 - 700